Thank you for your interest in Chronic Diseases and Translational Medicine. Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.
Free Format submission
Chronic Diseases and Translational Medicine now offers Free Format submission for a simplified and streamlined submission process.
Cover letter
A cover letter should be included in the ‘Cover Letter Field’ of the ScholarOne system. The text can be entered directly into the field or uploaded as a file.
The cover letter must contain:
i) A statement confirming the paper has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium;
ii) An acknowledgment that all authors have contributed significantly and in keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author’s contribution to the paper is to be described, i.e., what role each author participated in;
iii) a statement confirming that all authors are in agreement with the content of the manuscript.
Submission
Once you have prepared your submission in accordance with the Guidelines, manuscripts should be submitted online at https://mc.manuscriptcentral.com/cdtm
We look forward to your submission.
Chronic diseases have become a major challenge to human health globally. The aim of Chronic Diseases and Translational Medicine is to promote the prevention, diagnosis and treatment of chronic diseases by providing a forum for communicating the latest research advances from preclinical, translational, and clinical researchers from all established and emerging disciplines relevant to chronic diseases.
3. MANUSCRIPT CATEGORIES AND REQUIREMENTS
(1) Editorial
Word Limit: 1500 words maximum. Abstract: not required. References: 5 maximum.
Description: Proposals for Editorials may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration.
(2) Review
Word limit: 5000 words maximum including abstract but excluding references, tables and figures. Abstract: 250 words maximum, unstructured (no use of sub-headers). References: no limit. Figures/tables: maximum 6 images or figures.
Description: Review should not simply summarize information, but also discuss the importance and impact of the data providing a clear view on how these insights have transformed or will transform the field. Authors of review articles are encouraged to include several figures and tables to summarize and visualize data.
(3) Meta Analysis
Word limit: 4000 words maximum including abstract but excluding references, tables and figures. Abstract: 250 words maximum, with sub-headers. References: no limit. Figures/tables: no limit, but 8 figures should be sufficient.
Description: Meta analysis articles could be submitted by any author and are composed of a systematic review, mixed treatment compariaon, meta-regression and overview of reviews and provide a summary of a given quantitative effect.
(4) Perspective
Word limit: 3000 words maximum. Figures and tables: Up to 4 figures and tables in total. References: No more than 70 references.
Description: Perspectives discuss published findings and ideas from a personal viewpoint. They are more forward looking and /or speculative than Reviews. Perspectives can be submitted either by the invitations from the Editors or by the authors themselves. Both types will undergo the peer-review process prior to acceptance.
(5) Study Protocol
Word limit: 5000 words maximum including abstract but excluding references, tables and figures. Abstract: 250 words maximum, with sub-headers of Introduction, Methods, Discussion. Registration details (trial registration number and date of registration) should be included as the last line, if appropriate. References: no limit. Figures/tables: no limit, but 8 figures should be sufficient.
Description: Protocol papers should report planned or ongoing studies. Manuscripts describing long term studies and those likely to generate a considerable amount of outcome data are given preference. The following protocol papers are not considered: (a) Manuscripts that report work already carried out. (b) Authors have other articles relating to the protocol published or under consideration. (c) Protocol papers for pilot or feasibility studies (d) Protocol papers without ethics approval.
Peer Review: Chronic Diseases and Translational Medicine will consider publishing without peer review protocols that have formal ethics approval and a grant from a recognized major funding body. Please provide proof that these criteria are met when uploading your protocol. Manuscripts without major external funding, or where the Editor considers it necessary, will be peer reviewed. The final decision on whether to consider a study protocol for publication will rest with the Editor.
Randomized trials: Protocols of randomized trials should follow the SPIRIT guidelines, including the SPIRIT flow diagram in the main body of the text, with the populated checklist provided as an additional file.
(6) Original Article
Word limit: 4000 words maximum including abstract but excluding references, tables and figures. Abstract: 250 words maximum, with sub-headers. References: no limit. Figures/tables: no limit, but 8 figures should be sufficient.
Description: Full-length reports of current research in either basic or clinical science.
(7) Brief Report
Word limit: 1500 words including abstract but excluding references, tables and figures. Abstract: Not required. Keywords: Not required. References: 35 maximum. Figures/tables: 4 maximum in total.
Description: Manuscripts containing pertinent and interesting observations concerning chronic diseases and translational medicine research and reports on new observations or studies that do not warrant publication as a full research article will be considered for the Brief Reports. These submissions will undergo full peer review.
(8) Short Communication
Word limit: 2000 words maximum excluding references, tables and figures. Reference limit: 25 maximum. Figure/table limit: 2 maximum. Abstract: Not required. Keywords: Not required.
Description: Short Communications are miscellaneous articles of special interest to the medical community, especially for the presentation of research that extends previously published research, including the reporting of additional controls and confirmatory results in other settings, as well as negative results. Authors must clearly acknowledge any work upon which they are building, both published and unpublished.
(9) Commentary
Word limit: 1500 words maximum excluding references. Abstract: not required. References: 20 maximum, including the article discussed. Figures/tables: 2 maximum.
Description: Commentary, upon Editor’s invitation, discusses a paper published in a specific issue and should set the problems addressed by the paper in the wider context of the field. Proposals for Commentaries may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration.
(10) Correspondence
Word limit: 800 words maximum excluding references, tables and figures. Reference: 10-15 maximum. Figure/table limit: 1 maximum. Author limit: 5 maximum. Main text: This should contain the body of the article, and may also be broken into subsections with short, informative headings. Abstract: Not required. Keywords: Not required.
Description: Correspondence is usually peer reviewed and also may be considered at the discretion of the editor. The journal might invite replies from the authors of the original publication. The accepted correspondence may be edited for clarity or length and proofs will be sent out to authors before publication.
Style of the Manuscript
Manuscripts must follow the style detailed in the International Committee of Medical Journal Editors’ revised Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication.
Format Chronic Diseases and Translational Medicine now offers Free Format submission for a simplified and streamlined submission process. You could prepare the main text file using Microsoft Word without worrying about formatting requirements.
Spelling The journal uses US spelling and authors should therefore follow the latest edition of the Merriam–Webster’s Collegiate Dictionary.
Units All measurements must be given in SI or SI-derived units. For more information about SI units, please go to the Bureau International des Poids et Mesures (BIPM) website at: http://www.bipm.fr/
Abbreviations Must be used sparingly – only where they ease the reader’s task by reducing repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.
Trade names Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name, and the name and location of the manufacturer, in parentheses.
Parts of the Manuscript
The manuscript should be submitted in separate files: title page; main text file; figures; and supplementary files if required. Chronic Diseases and Translational Medicine uses double-blind peer review. To facilitate this, please include the following separately:
Title page (with author details): This should include the title, authors' names, affiliations, acknowledgements and any Declaration of Interest statement, and a complete address for the corresponding author including an e-mail address.
Anonymized manuscript (no author details): The main body of the paper (including the references, figures, tables and any acknowledgements) should not include any identifying information, such as the authors' names or affiliations.
Title Page File
The title page should contain:
i. The title and running title (less than 40 characters) of the paper. Concise titles are easier to read than long, convoluted ones. Titles that are too short may, however, lack important information, such as study design (which is particularly important in identifying randomized controlled trials). Authors should include all information in the title that will make electronic retrieval of the article both sensitive and specific.
ii. The full names of the authors;
iii. The addresses of the institutions at which the work was carried out (the present address of any author, if different from that where the work was carried out, should be supplied in a footnote);
iv. The full postal and email address, plus telephone numbers, of the author to whom correspondence about the manuscript should be sent, and note that only one corresponding author is permitted.
Author name
Each author’s given name should be followed by family name. Capitalize each letter of the family name.
Hyphens can be used in the family name according to the rules use in the author's region.
Capitalize the first letter of those words/syllables that they hope to be abbreviated in their given name, otherwise, DO NOT capitalize the first letter and use a hyphen to connect it with its anterior word.
Main Text File
The main text file should be presented in the following order:
i. Title;
ii. Abstract;
iii. Key points;
iv. Key words;
v. Text;
vi. Acknowledgments;
vii. Disclosure;
viii. References;
ix. Tables (each table complete with title and footnotes);
x. Figure legends.
Figures and supplementary material should be supplied as separate files.
Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.
Abstract
The length of abstracts must adhere to the word count specifications under the section Manuscript Categories. The abstract should state the main problem, methods, results, and conclusions. It must be factual and comprehensive. The use of abbreviations and acronyms should be limited and general statements (e.g. 'the significance of the results is discussed') should be avoided.
Key points
Authors are required to individually list and provide responses to the following two questions about the significant findings of the study, using a maximum of 40 words for each answer. Bullet points are allowed.
• Significant findings of the study
• What this study adds
Key words
Three to five key words should be supplied below the abstract, in alphabetical order, and should be taken from those recommended by the US National Library of Medicine’s Medical Subject Headings (MeSH) browser list.
Text
Authors should use the subheadings required for the Article Type as specified in the section 'Manuscript Categories'. Original Article manuscripts should be structured using the following sections: Introduction, Methods, Results, Discussion.
Acknowledgements
This should include sources of support/funding, including federal and industry support. All authors who have contributed to the manuscript must be acknowledged any federal and industry support/funding received. Medical writers, proofreaders and editors should not be listed as authors, but acknowledged here in the acknowledgements section.
Disclosure
All articles are required to include a disclosure statement. The statement should disclose all potential conflicts of interest, including specific financial interests and relationships and affiliations (other than those affiliations listed in the title page of the manuscript) relevant to the subject of their manuscript. Authors without conflicts of interest should include a statement of no such interests in the Disclosure section of the manuscript. Failure to include this information in the manuscript may delay evaluation and review of the manuscript.
Especially, for an article authorized by editorial board including Editor-in-Chief, Associate Editors, Editorial Board Members and Advisory Board Members, the statement "Professor xx is a member of Chronic Diseases and Translational Medicine editorial board and is not involved in the peer review process of this article" should be disclosed.
References
The American Medical Association (AMA) system of referencing should be used see the - AMA Manual of Style for details. All references should be numbered consecutively in order of appearance and should be as complete as possible. In text citations should cite references in consecutive order using Arabic superscript numerals. Sample references follow:
In-Text examples:
Diabetes mellitus is associated with a high risk of foot ulcers.1-3
Several interventions have been successful at increasing compliance.11,14-16
The data of Smith et al18 is further evidence of this effect.
As reported previously,1,3-6
The results were as follows4:
Journal article (1-6 authors):
1. King VM, Armstrong DM, Apps R, Trott JR. Numerical aspects of pontine, lateral reticular, and inferior olivary projections to two paravermal cortical zones of the cat cerebellum. J Comp Neurol 1998; 390:537-551.
Journal article with more than six authors:
2. Geller AC, Venna S, Prout M, et al. Should the skin cancer examination be taught in medical school? Arch Dermatol. 2002;138:1201-1203.
Journal article with no named author or group name:
3. Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use--Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59:273.
Online articles not yet published in an issue:
4. Smith JJ, Fihn SD, White RH. Treatment of allergic rhinitis. Am J Med. In press; doi:10.1016/S0002-9343(00)00545-3.
Book:
5. Voet D, Voet JG. Biochemistry. New York: John Wiley & Sons; 1990. 1223 p.
Book chapter:
6. Guyton JL, Crockarell JR. Fractures of acetabulum and pelvis. In: Canale ST, ed. Campbell's Operative Orthopaedics. 10th ed. Philadelphia, PA: Mosby, Inc; 2003:2939-2984.
Electronic book:
7. Rudolph CD, Rudolph AM. Rudolph's Pediatrics. 21st ed. New York, NY: McGraw-Hill Companies; 2002. http://online.statref.com/Document/Document.aspx?DocID=1&StartDoc=1&EndDoc=1882&FxID=13&offset=7&SessionId=A3F279FQVVFXFSXQ. Accessed August 22, 2007.
Internet document:
8. American Cancer Society. Cancer Facts & Figures 2003. http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf. Accessed March 3, 2003.
Graphical abstracts
Chronic Diseases and Translational Medicine publishes graphical abstracts for each article, displayed online in graphical form with a brief abstract (in addition to the <250 word abstract above).
The online table of contents will display a schematic figure to convey the core message of your paper, alongside a short abstract highlighting the major findings of the paper. Authors should submit a new and stand-alone image, not already included in the paper. Your graphical abstract should be simple, colourful and contain minimal text to attract additional readers. Your short abstract should consist of 2-3 sentences (max 500 characters with spaces) summarising the key findings presented in the paper. Graphical abstract entries should be submitted to Scholar One in one of the generic file formats and uploaded as ‘Graphical Abstract’ during the initial manuscript submission process. The image should be supplied as a tif or a pdf and fit within the dimensions of 50mm x 60mm, and be fully legible at this size.
Tables
Tables should be self-contained and complement, but not duplicate, information contained in the text. Number tables consecutively in the text in Arabic numerals. Type tables on a separate page with the legend above. Legends should be concise but comprehensive – the table, legend and footnotes must be understandable without reference to the text. Vertical lines should not be used to separate columns. Column headings should be brief, with units of measurement in parentheses; all abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.
Figure legends
Type figure legends on a separate page after References or Tables if the manuscript includes them. Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.
Figures
All illustrations (line drawings and photographs) are classified as figures. Figures should be cited in consecutive order in the text. Magnifications should be indicated using a scale bar on the illustration.
Size: Figures should be sized to fit within the column (80.5 mm), intermediate (112 mm) or the full text width (168 mm).
Text sizing in figures: Lettering must be included and should be sized to be no larger than the journal text or 8 point (Should be readable after reduction – avoid large type or thick lines). Line width between 0.5 and 1 point.
Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted.
Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.
Supporting Information
Supporting information is information that is not essential to the article, but provides greater depth and background. It is hosted online and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc.
Click here for Wiley’s FAQs on supporting information.
Note: if data, scripts, or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.
Pre-acceptance English-language editing
Authors for whom English is a second language may choose to have their manuscript professionally edited before submission to improve the English. Visit our site to learn about the options. All services are paid for and arranged by the author. Please note using the Wiley English Language Editing Service does not guarantee that your paper will be accepted by this journal.
Optimising Your Article for Search Engines
Many students and researchers looking for information online will use search engines such as Google, Yahoo or similar. By optimising your article for search engines, you will increase the chance of someone finding it. This in turn will make it more likely to be viewed and/or cited in another work. We have compiled these guidelines to enable you to maximise the web-friendliness of the most public part of your article.
5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS
Review Process
Chronic Diseases and Translational Medicine uses double-blind peer review, which means the identities of the authors are concealed from the reviewers, and vice versa.
Manuscripts are assigned sequentially to Associate Editors. An Associate Editor solicits reviewers (typically, two external reviews are sought). The reviewers’ evaluations and Associate Editor’s comments are compiled by the Editor-in-Chief for disposition and transmittal to the authors. A decision is made usually within six weeks of the receipt of the manuscript.
The Editor-in-Chief will advise authors whether a manuscript is accepted, should be revised or is rejected. Minor revisions are expected to be returned within two weeks of decision; major revisions within one month. Manuscripts not revised within these time periods are subject to withdrawal from consideration for publication unless the authors can provide extenuating circumstances.
A number of manuscripts will have to be rejected on the grounds of priority and available space. A manuscript may be returned to the authors without outside review if the Editor-in-Chief and Associate Editor find it inappropriate for publication in the Journal. Similarly, the Editors may expedite the review process for manuscripts felt to be of high priority in order to reach a rapid decision. Such ‘fast-track decisions’ will normally occur within one week of receipt of the manuscript.
Authors may provide the Editor-in-Chief with the names, addresses and email addresses of up to three suitably qualified individuals of international standing who would be competent to referee the work, although the Editor-in-Chief will not be bound by any such nomination. Likewise, authors may advise of any individual who for any reason, such as potential conflict of interest, might be inappropriate to act as a referee, again without binding the Editor-in-Chief.
The Editor-in-Chief’s decision is final. If, however, authors dispute a decision and can document good reasons why a manuscript should be reconsidered, a rebuttal process exists. In the first place, authors should write to the Editor-in-Chief.
If authors are from the editorial board of Chronic Diseases and Translational Medicine including Editor-in-Chief, Associate Editors, Editorial Board Members and Advisory Board Members, they will be excluded from the peer-review process and all editorial decisions related to the publication of this article.
Authorship and Acknowledgements
The journal adheres to the definition of authorship set up by The International Committee of Medical Journal Editors (ICMJE). The ICMJE recommends that authorship be based on the following 4 criteria:
i. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work;
ii. Drafting the work or revising it critically for important intellectual content;
iii. Final approval of the version to be published; and
iv. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Contributors who do not qualify as authors should be mentioned under ‘Acknowledgements’.
Disclosure
At the time of submission, the submitting author must include a disclosure statement in the body of the manuscript. All authors are required to disclose all potential conflicts of interest, including specific financial interests and relationships and affiliations (other than those affiliations listed in the title page of the manuscript) relevant to the subject of their manuscript. This information should be provided under the heading titled ‘Disclosure,’ which should appear after the ‘Acknowledge’ section and before the ‘References’ section. Authors without conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject of their manuscript, should include a statement of no such interests in the Disclosure section of the manuscript. Failure to include this information in the manuscript may delay evaluation and review of the manuscript. In addition, any financial interests must be detailed in the Financial Disclosure form, which will be provided to the corresponding author upon acceptance for distribution to each author.
Human Studies and Subjects
For manuscripts reporting medical studies that involve human participants, a statement identifying the ethics committee that approved the study and confirmation that the study conforms to recognized standards is required, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice. It should also state clearly in the text that all persons gave their informed consent prior to their inclusion in the study.
Patient anonymity should be preserved. Photographs need to be cropped sufficiently to prevent human subjects being recognized (or an eye bar should be used). Images and information from individual participants will only be published where the authors have obtained the individual's free prior informed consent. Authors do not need to provide a copy of the consent form to the publisher; however, in signing the author license to publish, authors are required to confirm that consent has been obtained. Wiley has a standard patient consent form available for use.
Use of Animals in Research
A statement indicating that the protocol and procedures employed were ethically reviewed and approved, as well as the name of the body giving approval, must be included in the manuscript. Authors are encouraged to adhere to animal research reporting standards, for example the ARRIVE guidelines for reporting study design and statistical analysis; experimental procedures; experimental animals and housing and husbandry. Authors should also state whether experiments were performed in accordance with relevant institutional and national guidelines for the care and use of laboratory animals.
Clinical Trial Registration
The journal requires that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Authors are asked to include the name of the trial register and the clinical trial registration number at the end of the abstract. If the trial is not registered, or was registered retrospectively, the reasons for this should be explained.
Clinical Trials Registry
We require, as a condition of consideration for publication, registration in a public trials registry. Trials must register at or before the onset of patient enrollment. This policy applies to any clinical trial starting enrollment after January 1, 2006. For trials that began enrollment before this date, we require registration by April 1, 2006, before considering the trial for publication. We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g., phase 1 trials) are exempt.
We do not advocate one particular registry, but registration must be with a registry that meets the following minimum criteria: (1) accessible to the public at no charge; (2) searchable by standard, electronic (Internet-based) methods; (3) open to all prospective registrants free of charge or at minimal cost; (4) validates registered information; (5) identifies trials with a unique number; and (6) includes information on the investigator(s), research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow-up, target number of subjects, status (anticipated, ongoing or closed) and funding source(s).
Registries that currently meet these criteria include: (1) the registry sponsored by the United States National Library of Medicine; (2) the International Standard Randomized Controlled Trial Number Registry; (3) the Australian New Zealand Clinical Trials Registry (ANZCTR); (4) the Chinese Clinical Trials Register; and (5) the Clinical Trials Registry - India.
Randomized control trials
Reporting of randomized controlled trials should follow the guidelines of The CONSORT Statement.
Protocols of randomized trials should follow the SPIRIT guidelines, including the SPIRIT flow diagram in the main body of the text, with the populated checklist provided as an additional file.
Reproduction of Copyright Material
If excerpts from copyrighted works owned by third parties are included, credit must be shown in the contribution. It is the author’s responsibility to also obtain written permission for reproduction from the copyright owners. For more information visit Wiley’s Copyright Terms & Conditions FAQ at http://exchanges.wiley.com/authors/faqs---copyright-terms--conditions_301.html
Associate your ScholarOne account with your ORCID iD
ORCID iD is a unique and persistent identifier that distinguishes you from every other researcher and connects you and your research activities. We encourage you to register for an ORCID iD and then associate it with your ScholarOne account. Click here to find out how.
Publication Ethics
This journal is a member of the Committee on Publication Ethics (COPE). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley'sTop 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found here.
Chronic Diseases and Translational Medicine is an Open Access journal that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
For an accepted paper, authors or their funding body pay an Article Publication Charge and publish their article under the copyright terms of a Creative Commons agreement. If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.
The following license agreement is used for Chronic Diseases and Translational Medicine :
Mandated authors such as RCUK or Wellcome trust funded authors will be directed to sign the open access agreement under the terms of the Creative Commons Attribution (CC-BY) license in order to be funder compliant.
All other authors choose between Creative Commons Attribution NonCommercial (CC-BY-NC) and Creative Commons Attribution NonCommercial NoDerivatives (CC-BY-NC-ND)
For more information on the terms and conditions of these licenses, please visit: http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html
Publication fees: To cover the cost of publishing, Chronic Diseases and Translational Medicine charges a publication fee when a submission is accepted for publication. There is no fee for initial submission for editorial/peer-review evaluation. Currently, the Article Publication Charge is waived for all accepted manuscripts. The Article Publication Charge will be collected after the journal receives the Impact Factor. Chronic Diseases and Translational Medicine's publication charge for authors submitting to the journal is 2650 USD. Agreement to pay the APC is given at manuscript submission but will only be charged upon acceptance.
7. PUBLICATION PROCESS AFTER ACCEPTANCE
Accepted article received in production
When an accepted article is received by Wiley’s production team, the corresponding author will receive an email asking them to login or register with Wiley Author Services. The author will be asked to sign a publication license and pay the Article Publication Charge at this point (Currently, the Article Publication Charge is waived for all accepted manuscripts).
Proofs
Once the paper is typeset, the author will receive an email notification with full instructions on how to provide proof corrections.
Early View
The journal offers rapid speed to publication via Wiley’s Early View service. Early View (Online Version of Record) articles are published on Wiley Online Library before inclusion in an issue. Note there may be a delay after corrections are received before the article appears online, as Editors also need to review proofs. Once the article is published on Early View, no further changes to the article are possible. The Early View article is fully citable and carries an online publication date and DOI for citations.
Access and sharing
When the article is published online the author receives an email alert (if requested).
Printed Offprints
Printed offprints may be ordered online for a fee. Please click on the following link and fill in the necessary details and ensure that you type information in all of the required fields: www.sheridan.com/wiley/eoc.
Promoting the Article
To find out how to best promote an article, click here.
Measuring the Impact of an Article
Wiley also helps authors measure the impact of their research through specialist partnerships with Kudos and Altmetric.
Wiley’s Author Name Change Policy
In cases where authors wish to change their name following publication, Wiley will update and republish the paper and redeliver the updated metadata to indexing services. Our editorial and production teams will use discretion in recognizing that name changes may be of a sensitive and private nature for various reasons including (but not limited to) alignment with gender identity, or as a result of marriage, divorce, or religious conversion. Accordingly, to protect the author’s privacy, we will not publish a correction notice to the paper, and we will not notify co-authors of the change. Authors should contact the journal’s Editorial Office with their name change request.
9. EDITORIAL OFFICE CONTACT DETAILS
Yi Cui
Editorial Director
Chronic Diseases and Translational Medicine Editorial office
No.69, East Heyan Street, Beijing 100052, China
E-mail: Cdtm@cmaph.org
